Beyond the Basics: How to Stack Peptides Inside Your Cycle

Stacking for Synergy, Not Volume

A peptide stack makes the most sense when each compound does a different job. Throwing three or four compounds together because you saw it on a forum mostly adds cost and makes side effects hard to trace. In a well-built stack, each component amplifies another or fills a specific gap.

The classic example is the GHRH and GHRP combination. A GHRH like Modified GRF 1-29 tells the pituitary how much growth hormone to release, while a GHRP like Ipamorelin tells it when to release it. In a 1990 study of 18 healthy men, IV doses of a GHRP given with GHRH released more growth hormone than either alone. As of October 2026, no controlled human trial has tested the Mod GRF 1-29 plus ipamorelin combination users actually run.

Contrast that with stacking two GHRPs, like GHRP-6 and Ipamorelin. They both act on the same receptor (the GHS-R1a receptor), so instead of synergy you get two compounds competing for one target. The same logic argues for giving every peptide a defined job that fits the training phase.

Phase I: The Off-Season Mass Stack (Weeks 1-12)

This is the foundational phase. The goal is straightforward: build lean tissue. Training usually centers on progressive overload with heavy compound lifts, and nutrition is in a surplus. Users build the stack around that stimulus.

This is where the GHRH + GHRP combo usually serves as the base, raising GH and, consequently, IGF-1. Whether that becomes more muscle is less clear: in a trial of the oral secretagogue MK-677 in 65 healthy older adults, fat-free mass rose about 1.1 kg over a year, but strength and function didn't change.

The Foundational Mass Stack

None of these doses comes from a trial, and no human dose has been tested for IGF-1 LR3 (forum users more often describe 20-50 mcg/day). Our IGF-1 LR3 profile covers the rat data and hypoglycemia reports.

Users typically inject the CJC-1295 and Ipamorelin together upon waking, post-workout, and before bed, on an empty stomach so insulin doesn't blunt the GH pulse; we found no study testing that timing for these peptides. IGF-1 LR3 is usually injected right after training, on the untested idea that worked muscle is more receptive.

Phase II: The Intensification or Pre-Contest Stack (Weeks 9-16)

Deeper into a training cycle, or at the start of a cutting phase, the demands change. Training gets closer to the limit, recovery capacity is stretched, and joints start talking back. On a diet, the priority shifts to keeping muscle and losing fat. Users adjust the stack to match.

This is where users add compounds for repair and metabolic effects. Most keep the GH base, which lifters run for recovery and lipolysis (neither measured in trials of these peptides), and add tools for specific problems.

The most common addition is a repair peptide. As volume and intensity climb, tendon and ligament strain becomes the limiting factor for many lifters, and BPC-157 and TB-500 come up most. The evidence for both is mostly animal data: BPC-157 has rodent healing studies and three small uncontrolled human pilots, and FDA says it has found no human exposure data for the TB-500 fragment. The only human data on the pair is one uncontrolled retrospective series of knee injections.

For a cutting phase, some users add a peptide focused on lipolysis. Tesamorelin has real clinical data: it's a GHRH analog sold as the prescription medicine Egrifta, approved only to reduce excess abdominal fat in adults with HIV-associated lipodystrophy, and its label says it isn't for weight loss. In a 2014 trial in 50 such patients, 2 mg daily for 6 months reduced visceral adipose tissue versus placebo. HGH Fragment 176-191 also comes up, but human trials of its modified form, AOD-9604, used oral or IV dosing and mostly showed no weight benefit over placebo.

• Keep the Base: Most users continue the CJC-1295/Ipamorelin stack, citing recovery.
• Add for Repair: BPC-157 at 250 mcg twice daily is a common user report (the wider community range is 250-500 mcg/day), taken for connective tissue rather than muscle growth. Rodent studies link its effects partly to angiogenesis (new blood vessel growth). For TB-500, vendor guidance describes 2-2.5 mg twice weekly for 4-6 weeks, then monthly maintenance; no human dose has been tested for the fragment. See our TB-500 profile.
• Add for Fat Loss (if cutting): Some users report adding tesamorelin at 1 mg before bed. The main trials used 2 mg daily, and the newer Egrifta WR is labeled at 1.28 mg daily. Since tesamorelin is itself a GHRH analog, adding it to CJC-1295 is the same-class overlap described above. Research-use vials aren't the same as the prescription product.

The Taper and Bridge: Coming in for a Smooth Landing

No stack runs at full output forever. Users taper to let the system return to baseline and receptors resensitize before the next cycle. In a 16-week study of twice-daily hexarelin (a GHRP) in 12 healthy older adults, the GH response fell by roughly 45%, then fully recovered four weeks after stopping. Whether a gradual taper beats stopping outright hasn't been studied; the schedule below is community practice.

For the last 2-4 weeks, the usual approach is to drop the most potent, long-acting compounds first. If the stack included CJC-1295 with DAC (the long-acting version), that's usually the first to go. Users then halve the dose of the pulsatile peptides.

• Weeks 1-2 of Taper: Users stop any long-acting GHRH (like CJC with DAC) and any specialized compounds (like IGF-1 LR3 or tesamorelin).
• Weeks 1-2 of Taper: The short-acting stack (e.g., CJC no DAC/Ipamorelin) is commonly cut by 50%. Many users drop to a single dose before bed, aiming to avoid a sharp drop-off while receptors begin resetting.
• Weeks 3-4 (The Bridge): All GH-related peptides stop. Some users run a recovery-only protocol with BPC-157 and/or TB-500 here. Nothing in this phase stimulates the pituitary; the focus is on healing before the next heavy block of training. Our peptide cycling overview covers on/off schedules in more detail.

Stacking Sins and Diminishing Returns

More compounds don't mean better results. Stacks of five to seven peptides show up regularly in forum posts, and with that many variables there's no way to tell what's working or what's causing a side effect.

The most common mistakes:

1. Redundancy: As mentioned, stacking two peptides from the same class (e.g., two GHRPs, or two GHRH analogs) adds cost without a clear added effect. Community advice is to pick one compound per class.
2. Ignoring Saturation: Community guides say GHRPs hit a 'saturation dose' around 1 mcg/kg (roughly 100 mcg), so 500 mcg won't give 5x the release. We couldn't trace a primary source for that cutoff. In the 1990 Bowers study, GH release was still climbing at 1 mcg/kg IV, but that dose was also the only one that roughly doubled cortisol and prolactin.
3. The 'Fix-a-Bad-Diet' Stack: No combination of peptides makes up for a poor diet. Tesofensine (not a peptide), Fragment 176-191, or anything else can't outrun a high-calorie, nutrient-poor intake. At best, peptides add to a good protocol; they don't replace one.
4. Cost vs. Benefit: A fourth or fifth peptide might add a small improvement, if any. Whether that's worth an extra $200 a month depends on the goal: a competitor a week out from a show may judge it differently from a recreational lifter. In community reports, most of the perceived benefit comes from the base stack, and each addition costs more for less.

What We Still Don't Know

Phased stacking is a community framework, not a tested protocol. As of October 2026, no controlled human trial has tested any multi-peptide stack, and there are no human data on IGF-1 LR3 or the TB-500 fragment. Desensitization data barely go beyond the hexarelin study above, so cycle and taper lengths are educated guesses; our article on long-term effects of peptide cycling looks at longer time frames.

For tested athletes, WADA's 2026 Prohibited List bans the main peptides here at all times: CJC-1295, tesamorelin and ipamorelin under S2.2.4, IGF-1 analogues and TB-500 under S2.3, and BPC-157 under S0.